The Cytokine Suppressor CIS in Giant Cell Pneumonitis
Project Number5R01HL148337-03
Contact PI/Project LeaderYANG, XUEXIAN
Awardee OrganizationUNIVERSITY OF NEW MEXICO HEALTH SCIS CTR
Description
Abstract Text
Project Summary
Giant cell pneumonitis (GCP) is a collection of fatal chronic diseases, including hard metal lung
disease, virus-associated GCP and non-hard metal, non-infectious GCP. Regardless of the
etiology, GCP is characterized by the presence of alveolar macrophage-derived multinucleate
giant cells (MGCs) that together with other immune infiltrates obstruct alveolar spaces and cause
lung failure. Little is known on the pathogenesis of GCP, which is largely due to lack of
appropriate animal models, and there is no effective treatment, presenting a critical knowledge
gap. In this proposal, we will close an aspect of this knowledge gap by using a unique animal
model of GCP we recently developed to investigate the immunological mechanisms that lead to
this fatal disease. Hard metal (such as cobalt) workers had elevated levels of serum IgE, a CD4+
T helper (TH) 2 cell-dependent antibody isotype, and patients with hard metal GCP contained
increased numbers of T cells in their bronchoalveolar lavage fluids (BALFs), implicating a
potential role of T cells in the pathology of GCP. However, it is entirely unclear how dysregulation
of TH cells causes MGC formation, resulting in the development of GCP. Our long-term goal is to
dissect the mechanisms underlying the pathogenesis of GCP; the discoveries may lead to novel
therapeutic options. The scientific premise of this proposal is strongly supported by our
preliminary studies that CIS, a member of the suppressor of the cytokine signaling (SOCS) family,
is required to suppress GCP, which is likely via a T cell-dependent manner; Cis-deficiency in mice
leads to formation and accumulation of MGCs with increased numbers of TH cells in the lungs
and causes severe obstruction of alveoli, leading to even death. Our central hypothesis is that CIS
inhibits MGC formation via restricting TH cell responses, therefore preventing GCP. The Specific
Aims are: Aim 1. Determine the TH cell-intrinsic role of CIS in the development of GCP. Aim 2.
Delineate the mechanism underlying the suppressive function of CIS in GCP, especially hard
metal lung disease.
Public Health Relevance Statement
Project Narrative
Giant cell pneumonitis (GCP) is a collection of fatal chronic diseases, which is
characterized by the presence of alveolar macrophage formed multinucleate giant cells
(MGCs) that together with other immune infiltrates obstruct alveolar spaces and cause
lung failure. Little is known on the pathogenesis of GCP, which is largely due to lack of
appropriate animal models, and there is no effective treatment, presenting a critical
knowledge gap. In this proposal, we will close an aspect of this knowledge gap by using
our unique animal model of GCP to investigate the immune mechanisms that lead to this
fatal disease. Studies on patients with hard metal-caused GCP implicate a potential role
of T cells in the pathology. Our preliminary studies demonstrated that CIS, a cytokine
signal suppressor, inhibits T cell responses and is required to suppress spontaneous
GCP in mice. We hypothesize that CIS inhibits MGC formation via restricting T cell
responses, therefore preventing GCP. By address our hypothesis, this study will pave a
novel avenue in understanding of GCP and may lead to new therapeutic opportunities.
This work has clear biomedical relevance to human GCP.
No Sub Projects information available for 5R01HL148337-03
Publications
Publications are associated with projects, but cannot be identified with any particular year of the project or fiscal year of funding. This is due to the continuous and cumulative nature of knowledge generation across the life of a project and the sometimes long and variable publishing timeline. Similarly, for multi-component projects, publications are associated with the parent core project and not with individual sub-projects.
No Publications available for 5R01HL148337-03
Patents
No Patents information available for 5R01HL148337-03
Outcomes
The Project Outcomes shown here are displayed verbatim as submitted by the Principal Investigator (PI) for this award. Any opinions, findings, and conclusions or recommendations expressed are those of the PI and do not necessarily reflect the views of the National Institutes of Health. NIH has not endorsed the content below.
No Outcomes available for 5R01HL148337-03
Clinical Studies
No Clinical Studies information available for 5R01HL148337-03
News and More
Related News Releases
No news release information available for 5R01HL148337-03
History
No Historical information available for 5R01HL148337-03
Similar Projects
No Similar Projects information available for 5R01HL148337-03